376 related articles for article (PubMed ID: 16191004)
1. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
4. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year.
Van Leent EJ; De Vries HJ; Ebelin ME; Burtin P; Scott G; Bos JD
J Dermatolog Treat; 2007; 18(1):19-22. PubMed ID: 17365262
[TBL] [Abstract][Full Text] [Related]
5. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.
Lakhanpaul M; Davies T; Allen BR; Schneider D
Exp Dermatol; 2006 Feb; 15(2):138-41. PubMed ID: 16433686
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
8. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
9. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
[TBL] [Abstract][Full Text] [Related]
10. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
11. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study.
Thaçi D; Steinmeyer K; Ebelin ME; Scott G; Kaufmann R
Dermatology; 2003; 207(1):37-42. PubMed ID: 12835546
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study.
Yan AC; Honig PJ; Ming ME; Weber J; Shah KN
Arch Dermatol; 2010 Jan; 146(1):57-62. PubMed ID: 20083693
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.
Siegfried E; Korman N; Molina C; Kianifard F; Abrams K
J Dermatolog Treat; 2006; 17(3):143-50. PubMed ID: 16854753
[TBL] [Abstract][Full Text] [Related]
14. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.
Papp KA; Werfel T; Fölster-Holst R; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C
J Am Acad Dermatol; 2005 Feb; 52(2):240-6. PubMed ID: 15692468
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Zuberbier T; Bräutigam M
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
17. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients.
Allen BR; Lakhanpaul M; Morris A; Lateo S; Davies T; Scott G; Cardno M; Ebelin ME; Burtin P; Stephenson TJ
Arch Dis Child; 2003 Nov; 88(11):969-73. PubMed ID: 14612358
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
